Cardiol Therapeutics Inc. (TSE:CRDL) Director Purchases C$75,072.00 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) Director David Elsley purchased 40,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were purchased at an average cost of C$1.88 per share, for a total transaction of C$75,072.00.

Cardiol Therapeutics Price Performance

CRDL stock traded up C$0.04 on Tuesday, reaching C$1.95. 137,013 shares of the company's stock were exchanged, compared to its average volume of 135,025. The stock has a fifty day moving average of C$2.41 and a 200-day moving average of C$2.73. Cardiol Therapeutics Inc. has a twelve month low of C$1.07 and a twelve month high of C$4.26. The firm has a market cap of C$136.27 million, a PE ratio of -4.43 and a beta of 0.70. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.